Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 212 clinical trials
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, …

blast cells
anthracyclines
mitoxantrone
gemtuzumab
methotrexate
  • 141 views
  • 10 May, 2022
  • 98 locations
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when …

direct bilirubin
anthracyclines
doxorubicin
glomerular filtration rate
acute leukemia
  • 310 views
  • 16 Sep, 2022
  • 170 locations
Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer (PRINCEPS)

Based on the efficacy of immunotherapies in advanced disease with a reasonable safety profile/tolerability we could hypothetisize that, immunotherapy should work best in the situation of minimal residual disease, Two clinical trials are ongoing to test the role of immunotherapeutic agents in the adjuvant setting: PEARLS trial, a randomized phase …

pembrolizumab
lung carcinoma
neutrophil count
ct scan
serum bilirubin level
  • 0 views
  • 25 Feb, 2022
  • 1 location
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated donors.

fludarabine
cytarabine
busulfan
daunorubicin
consolidation therapy
  • 0 views
  • 04 Oct, 2022
  • 1 location
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

The purpose of this study is to determine if using a subject's baseline frailty score to guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite).

lenalidomide
dexamethasone
  • 0 views
  • 23 Mar, 2022
  • 1 location
Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

The purpose of this study is to determine whether a diet intervention (the Fasting Mimicking diet) will help induce clinical and biochemical response to tofacitinib therapy or second line biologic therapy with ustekinumab or infliximab in patients with ulcerative colitis. Study period will be 8 weeks during induction of tofacitinib …

antibiotics
infliximab
  • 0 views
  • 14 May, 2022
  • 1 location
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

Individualized induction therapy will be applied to the non-elderly acute myeloid leukemia (AML) patients with adverse genetic risk features guided by rapid screening with fluorescence in situ

  • 0 views
  • 22 Nov, 2021
  • 1 location
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

The aim of this study is to evaluate the safety and efficacy of fluzoparib combined with abiraterone in neoadjuvant treatment of patients with high-risk localized prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.

  • 0 views
  • 10 May, 2022
  • 1 location
  • 1 views
  • 17 Feb, 2021
  • 4 locations
  • 0 views
  • 27 Apr, 2022
  • 2 locations